B. Riley Wealth Advisors Inc. Invests $574,000 in Danaher Corporation $DHR

B. Riley Wealth Advisors Inc. acquired a new stake in Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 2,905 shares of the conglomerate’s stock, valued at approximately $574,000.

Several other hedge funds have also recently bought and sold shares of DHR. White Pine Capital LLC increased its holdings in shares of Danaher by 1.4% during the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after acquiring an additional 49 shares during the last quarter. Boyd Watterson Asset Management LLC OH grew its holdings in Danaher by 2.1% during the second quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after purchasing an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC raised its position in shares of Danaher by 4.6% in the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after purchasing an additional 53 shares during the period. Bruce G. Allen Investments LLC lifted its stake in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after buying an additional 54 shares during the last quarter. Finally, Texas Bank & Trust Co boosted its holdings in shares of Danaher by 1.6% during the 2nd quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock worth $705,000 after buying an additional 55 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Down 1.7%

DHR opened at $224.72 on Wednesday. The company has a market capitalization of $158.73 billion, a P/E ratio of 46.33, a P/E/G ratio of 4.44 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The firm’s fifty day moving average price is $219.17 and its two-hundred day moving average price is $206.42. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the prior year, the company posted $1.71 EPS. The business’s revenue was up 4.4% on a year-over-year basis. On average, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be paid a dividend of $0.32 per share. The ex-dividend date is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Redburn Partners set a $220.00 target price on shares of Danaher in a research report on Wednesday, October 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research note on Wednesday, October 8th. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price target (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. TD Cowen increased their price objective on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Finally, Evercore ISI boosted their target price on shares of Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Twenty analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $247.21.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.